AbbVie announced that the Russian Ministry of Health approved Venclexta (venetoclax), a drug, for oral administration. The drug is a potent selective inhibitor of antiapoptotic protein of B-cell lymphoma.
Biogen and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing multiple sclerosis. The European Medicines Agency started an urgent review following the reports of eight cases of inflammation of the brain.
AbbVie and Voyager Therapeutics entered into a collaboration to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
AbbVie, a global biopharmaceutical company, announced today that data from multiple clinical trials evaluating venetoclax will be presented at the 22nd European Hematology Association (EHA) Annual Congress
AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor did...